ABSTRACT
Introduction In reviewing current and future strategies for the management of familial hypercholesterolaemia (FH), this chapter critically assesses the application of conventional clinical and DNA-based diagnostic tests, and the extent to which FH fulfils the accepted criteria required by a screening programme. The use of functional foods, advances in drug therapy, drug safety and the determinants of compliance are discussed in other chapters.
